{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T02:37:58Z","timestamp":1793587078946,"version":"4.5.0"},"reference-count":67,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ2093, 2023JJ40946, 2024JJ6647"],"award-info":[{"award-number":["2024JJ2093, 2023JJ40946, 2024JJ6647"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Youth Science Foundation of Xiangya Hospital","award":["2022Q20, 2023Q9"],"award-info":[{"award-number":["2022Q20, 2023Q9"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303760"],"award-info":[{"award-number":["82303760"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373337"],"award-info":[{"award-number":["82373337"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the China Postdoctoral Innovation Talents Support Program","award":["BX20230431"],"award-info":[{"award-number":["BX20230431"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M733951"],"award-info":[{"award-number":["2023M733951"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,7,16]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors have shown limited response rates in bladder cancer. RC48-antibody-drug conjugate (ADC) shows potential for combination with immune checkpoint inhibitors. This study aimed to elucidate RC48-ADC\u2019s mechanism in sensitizing tumors to immunotherapy and identify optimal combination strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bioinformatics (The Cancer Genome Atlas, GEO, Xiangya cohorts) analyzed correlations between HER2, immune markers, and therapy response. The h-HER2-MB49 and sg-PD-L1-MB49 cell line was generated. In vitro\/vivo models assessed RC48-ADC\u2019s impact on the tumor immune microenvironment using flow cytometry, immunofluorescence, co-culture, chemotaxis, CUT&amp;Tag assays, transcriptomics, and ELISA. Subcutaneous tumor models evaluated combination therapies. At the clinical level, bladder cancer immune therapy cohort tissue microarrays were used, and the aforementioned mechanisms were validated using immunohistochemistry and immunofluorescence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HER2 expression is associated with an inhibitory tumor immune microenvironment and resistance to immunotherapy. RC48-ADC treatment can reactivate this HER2-related inhibitory tumor immune microenvironment, thereby enhancing immunotherapy effectiveness. Mechanistically, RC48-ADC reactivates the tumor immune microenvironment by reducing PD-L1 transcription via Hippo pathway activation. It also promotes the release of chemokines (CCL5, CXCL9, and CXCL14) and recruits cytotoxic T-lymphocytes. In preclinical mouse models, RC48-ADC synergized with CTLA-4 and PD-L1 antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RC48-ADC enhances immunotherapy by regulating PD-L1 through the Hippo-TAZ pathway and reactivating CD8+T cells, offering a novel combination therapeutic strategy for bladder cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-011881","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T02:40:39Z","timestamp":1754966439000},"page":"e011881","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48"],"prefix":"10.1136","volume":"13","author":[{"given":"Jiatong","family":"Xiao","sequence":"first","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Liu","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital, Guizhou Medical University, Kaili, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Nie","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglin","family":"Yi","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisu","family":"Liang","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Huang","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Cai","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzhe","family":"Yan","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingquan","family":"Wu","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefu","family":"Liu","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Chen","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2049-6342","authenticated-orcid":false,"given":"Xiongbing","family":"Zu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Hunan Normal University, Hunan Normal University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Hu","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"2026052108402020000_13.8.e011881.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.029"},{"key":"2026052108402020000_13.8.e011881.2","unstructured":"Research CfDEa . FDA approves nivolumab for adjuvant treatment of urothelial carcinoma. FDA; 2024."},{"key":"2026052108402020000_13.8.e011881.3","unstructured":"Goodman A . Adjuvant pembrolizumab: a new option for high-risk muscle-invasive urothelial cancer."},{"key":"2026052108402020000_13.8.e011881.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"2026052108402020000_13.8.e011881.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0628-7"},{"key":"2026052108402020000_13.8.e011881.6","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2020.11.2.1"},{"key":"2026052108402020000_13.8.e011881.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140"},{"key":"2026052108402020000_13.8.e011881.8","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026052108402020000_13.8.e011881.9","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2069883"},{"key":"2026052108402020000_13.8.e011881.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2488"},{"key":"2026052108402020000_13.8.e011881.11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","article-title":"Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors","volume":"24","author":"Xu","year":"2021","journal-title":"Gastric Cancer"},{"key":"2026052108402020000_13.8.e011881.12","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00262-023-03419-1","article-title":"HER2-targeting antibody\u2013drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2026052108402020000_13.8.e011881.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-024-02981-5","article-title":"Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer","volume":"43","author":"Li","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"2026052108402020000_13.8.e011881.14","doi-asserted-by":"crossref","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2026052108402020000_13.8.e011881.15","doi-asserted-by":"crossref","first-page":"21159","DOI":"10.1002\/cam4.6680","article-title":"Real\u2010world effectiveness and safety of rc48\u2010adc alone or in combination with pd \u20101 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"key":"2026052108402020000_13.8.e011881.16","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-015-9552-6"},{"key":"2026052108402020000_13.8.e011881.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.035"},{"key":"2026052108402020000_13.8.e011881.18","first-page":"28","article-title":"Effect of different HER2 expression on the efficacy of immunotherapy for advanced urothelial carcinoma who failed the previous chemotherapy","volume":"43","author":"Siming","year":"2022","journal-title":"Chinese Journal of Urology"},{"key":"2026052108402020000_13.8.e011881.19","doi-asserted-by":"crossref","unstructured":"Ou Z , Hu J , Chen M , et al . Efficacy and safety of neoadjuvant therapy with disitamab vedotin plus toripalimab in treating muscle invasive urothelial bladder cancer followed by selective bladder-preserving or radical cystectomy. American Society of Clinical Oncology, 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.e16590"},{"key":"2026052108402020000_13.8.e011881.20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.trecan.2019.04.001","article-title":"Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities","volume":"5","author":"Calses","year":"2019","journal-title":"Trends Cancer"},{"key":"2026052108402020000_13.8.e011881.21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-013118-111829"},{"key":"2026052108402020000_13.8.e011881.22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.152942"},{"key":"2026052108402020000_13.8.e011881.23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2711"},{"key":"2026052108402020000_13.8.e011881.24","unstructured":"FDA grants breakthrough therapy designation to rc48 for urothelial cancer."},{"key":"2026052108402020000_13.8.e011881.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0694-x"},{"key":"2026052108402020000_13.8.e011881.26","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0749"},{"key":"2026052108402020000_13.8.e011881.27","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0464-1","article-title":"A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer","volume":"7","author":"D\u2019Amico","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026052108402020000_13.8.e011881.28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103345","article-title":"Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials","volume":"67","author":"Okada","year":"2021","journal-title":"EBioMedicine"},{"key":"2026052108402020000_13.8.e011881.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3"},{"key":"2026052108402020000_13.8.e011881.30","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202302377","article-title":"A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer","volume":"10","author":"Hong","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"2026052108402020000_13.8.e011881.31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M900843200"},{"key":"2026052108402020000_13.8.e011881.32","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.49"},{"key":"2026052108402020000_13.8.e011881.33","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202207155","article-title":"BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti\u2010PD\u20101\/PD\u2010L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity","volume":"10","author":"Cai","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"2026052108402020000_13.8.e011881.34","doi-asserted-by":"crossref","unstructured":"Li H , Chen J , Li Z , et al . S100A5 Attenuates Efficiency of Anti\u2010PD\u2010L1\/PD\u20101 Immunotherapy by Inhibiting CD8 + T Cell\u2010Mediated Anti\u2010Cancer Immunity in Bladder Carcinoma . Adv Sci (Weinh) 2023;10. doi:10.1002\/advs.202300110","DOI":"10.1002\/advs.202300110"},{"key":"2026052108402020000_13.8.e011881.35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007230","article-title":"Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8+ T cell infiltration and functional transition","volume":"11","author":"Yu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026052108402020000_13.8.e011881.36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2022.40.16_suppl.106","article-title":"A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R\/M CC)","volume":"40","author":"Wang","year":"2022","journal-title":"JCO"},{"key":"2026052108402020000_13.8.e011881.37","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1200\/JCO.2022.40.6_suppl.515","article-title":"Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma","volume":"40","author":"Zhou","year":"2022","journal-title":"JCO"},{"key":"2026052108402020000_13.8.e011881.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.09.030"},{"key":"2026052108402020000_13.8.e011881.39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406351101"},{"key":"2026052108402020000_13.8.e011881.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.12.003"},{"key":"2026052108402020000_13.8.e011881.41","doi-asserted-by":"crossref","unstructured":"Chung BS , Liao IC , Lin PC , et al . PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer-Its Clinical and Biological Significance in Immune Microenvironment. Int J Mol Sci 2022;23.","DOI":"10.3390\/ijms232113277"},{"key":"2026052108402020000_13.8.e011881.42","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.dld.2022.01.128","article-title":"PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance","volume":"54","author":"Lian","year":"2022","journal-title":"Dig Liver Dis"},{"key":"2026052108402020000_13.8.e011881.43","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0266-z"},{"key":"2026052108402020000_13.8.e011881.44","doi-asserted-by":"crossref","unstructured":"Yu J , Wang X , Teng F , et al . PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 2016;5023\u201339. doi:10.2147\/OTT.S105862","DOI":"10.2147\/OTT.S105862"},{"key":"2026052108402020000_13.8.e011881.45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02912"},{"key":"2026052108402020000_13.8.e011881.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.07.059"},{"key":"2026052108402020000_13.8.e011881.47","doi-asserted-by":"crossref","first-page":"1321946","DOI":"10.3389\/fimmu.2024.1321946","article-title":"Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"2026052108402020000_13.8.e011881.48","doi-asserted-by":"crossref","first-page":"102085","DOI":"10.1016\/j.clgc.2024.102085","article-title":"Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study","volume":"22","author":"Wang","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"2026052108402020000_13.8.e011881.49","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80406-9"},{"key":"2026052108402020000_13.8.e011881.50","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80089-8"},{"key":"2026052108402020000_13.8.e011881.51","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5502.319"},{"key":"2026052108402020000_13.8.e011881.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369"},{"key":"2026052108402020000_13.8.e011881.53","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30700-9"},{"key":"2026052108402020000_13.8.e011881.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946"},{"key":"2026052108402020000_13.8.e011881.55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6212"},{"key":"2026052108402020000_13.8.e011881.56","doi-asserted-by":"crossref","first-page":"28561","DOI":"10.18632\/oncotarget.25564","article-title":"Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer","volume":"9","author":"Boudadi","year":"2018","journal-title":"Oncotarget"},{"key":"2026052108402020000_13.8.e011881.57","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-11593-9","article-title":"RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cancer"},{"key":"2026052108402020000_13.8.e011881.58","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2017.1312230"},{"key":"2026052108402020000_13.8.e011881.59","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.3390\/cancers15205034","article-title":"YAP1 Expression in HR+HER2\u2212 Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation","volume":"15","author":"Park","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026052108402020000_13.8.e011881.60","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.537265","article-title":"The Hippo Transducer YAP\/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients","volume":"11","author":"Yuan","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026052108402020000_13.8.e011881.61","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3390\/cancers12051108","article-title":"The Hippo Pathway Transducers YAP1\/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer","volume":"12","author":"Gonz\u00e1lez-Alonso","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026052108402020000_13.8.e011881.62","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ebiom.2019.04.061","article-title":"Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1","volume":"43","author":"Islam","year":"2019","journal-title":"EBioMedicine"},{"key":"2026052108402020000_13.8.e011881.63","doi-asserted-by":"crossref","first-page":"101068","DOI":"10.1016\/j.drup.2024.101068","article-title":"Development and evaluation of a human CD47\/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy","volume":"74","author":"Zhang","year":"2024","journal-title":"Drug Resist Updat"},{"key":"2026052108402020000_13.8.e011881.64","doi-asserted-by":"publisher","DOI":"10.7150\/thno.53649"},{"key":"2026052108402020000_13.8.e011881.65","doi-asserted-by":"crossref","unstructured":"Hu J , Othmane B , Yu A , et al . 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer. BMC Med 2021;19. doi:10.1038\/s41401-023-01079-6","DOI":"10.1186\/s12916-021-02163-6"},{"key":"2026052108402020000_13.8.e011881.66","unstructured":"Kirk S , Lee Y , Lucchesi FR , et al . The Cancer Genome Atlas Urothelial Bladder Carcinoma Collection (TCGA-BLCA) (Version 8). The Cancer Imaging Archive 2016. doi:10.7937\/K9\/TCIA.2016.8LNG8XDR"},{"key":"2026052108402020000_13.8.e011881.67","doi-asserted-by":"crossref","unstructured":"Kovacs SA , Fekete JT , Gyorffy B . Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. Acta Pharmacol Sin 2023. doi:10.1038\/s41401-023-01079-6","DOI":"10.1038\/s41401-023-01079-6"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-011881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:40:36Z","timestamp":1779378036000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-011881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":67,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,11]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/jitc-2025-011881"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-011881","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}